Research Topics

Genomes and Genes

Species

Bing He Xu

Summary

Country: China

Publications

  1. request reprint
    Du F, Yuan P, Luo Y, Wang J, Ma F, Cai R, et al. [Efficacy and toxicity of vinorelbine (NVB)-based regimens in patients with metastatic triple negative breast cancer (mTNBC) pretreated with anthracyclines and taxanes]. Zhonghua Zhong Liu Za Zhi. 2015;37:788-92 pubmed
    ..NP regimen shows potential superiority over NX regimen, and should be further verified in randomized phase III clinical trial in larger cohort. ..
  2. request reprint
    Li Q, Xu B, Li Q, Zhang P, Yuan P, Wang J, et al. [Efficacy and safety of cisplatin plus capecitabine for patients with metastatic triple negative breast cancer progressing after anthracycline and taxane treatment]. Zhonghua Zhong Liu Za Zhi. 2015;37:938-41 pubmed
    ..7%), stomatitis (3.4%), and hand-foot syndrome (3.4%). Cisplatin and capecitabine combination therapy is an active and well-tolerated doublet treatment in metastatic TNBC patients progressing after anthracycline and taxane treatments. ..
  3. Chen X, Du F, Hong R, Wang J, Luo Y, Li Q, et al. Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer. Chin J Cancer. 2016;35:39 pubmed publisher
    ..8%) and hematologic abnormalities (7.6%). For HR-positive and HER2-negative MBC patients, HT might be considered a treatment after response to FCCT but prior to MCT as a long-term administration. ..
  4. request reprint
    Wu Y, Zhang L, Trandafir L, Dong T, Duval V, Hazell K, et al. Phase I Study of the Pan-PI3K Inhibitor Buparlisib in Adult Chinese Patients with Advanced Solid Tumors. Anticancer Res. 2016;36:6185-6194 pubmed
    ..The MTD of buparlisib was declared as 100 mg/day. Safety, efficacy and pharmacokinetic data from this study were similar to those previously reported in Western and Japanese populations. ..
  5. Hong R, Ma F, Zhang W, Yu X, Li Q, Luo Y, et al. Erratum to: 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells. BMC Cancer. 2016;16:925 pubmed
  6. Hong R, Ma F, Zhang W, Yu X, Li Q, Luo Y, et al. 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells. BMC Cancer. 2016;16:725 pubmed publisher
    ..These results suggest that 53BP1 may be a predictor of PARP inhibitor resistance in patients with ATM-deficient tumors. ..

Collaborators

Detail Information

Publications6

  1. request reprint
    Du F, Yuan P, Luo Y, Wang J, Ma F, Cai R, et al. [Efficacy and toxicity of vinorelbine (NVB)-based regimens in patients with metastatic triple negative breast cancer (mTNBC) pretreated with anthracyclines and taxanes]. Zhonghua Zhong Liu Za Zhi. 2015;37:788-92 pubmed
    ..NP regimen shows potential superiority over NX regimen, and should be further verified in randomized phase III clinical trial in larger cohort. ..
  2. request reprint
    Li Q, Xu B, Li Q, Zhang P, Yuan P, Wang J, et al. [Efficacy and safety of cisplatin plus capecitabine for patients with metastatic triple negative breast cancer progressing after anthracycline and taxane treatment]. Zhonghua Zhong Liu Za Zhi. 2015;37:938-41 pubmed
    ..7%), stomatitis (3.4%), and hand-foot syndrome (3.4%). Cisplatin and capecitabine combination therapy is an active and well-tolerated doublet treatment in metastatic TNBC patients progressing after anthracycline and taxane treatments. ..
  3. Chen X, Du F, Hong R, Wang J, Luo Y, Li Q, et al. Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer. Chin J Cancer. 2016;35:39 pubmed publisher
    ..8%) and hematologic abnormalities (7.6%). For HR-positive and HER2-negative MBC patients, HT might be considered a treatment after response to FCCT but prior to MCT as a long-term administration. ..
  4. request reprint
    Wu Y, Zhang L, Trandafir L, Dong T, Duval V, Hazell K, et al. Phase I Study of the Pan-PI3K Inhibitor Buparlisib in Adult Chinese Patients with Advanced Solid Tumors. Anticancer Res. 2016;36:6185-6194 pubmed
    ..The MTD of buparlisib was declared as 100 mg/day. Safety, efficacy and pharmacokinetic data from this study were similar to those previously reported in Western and Japanese populations. ..
  5. Hong R, Ma F, Zhang W, Yu X, Li Q, Luo Y, et al. Erratum to: 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells. BMC Cancer. 2016;16:925 pubmed
  6. Hong R, Ma F, Zhang W, Yu X, Li Q, Luo Y, et al. 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells. BMC Cancer. 2016;16:725 pubmed publisher
    ..These results suggest that 53BP1 may be a predictor of PARP inhibitor resistance in patients with ATM-deficient tumors. ..